Romidepsin

Therapeutic

For the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. 

Structural features

SMILES

C/C=C1C(N[C@@H](C(C)C)C(O[C@H]2CC(N[C@H](C(C)C)C(N[C@@H](C(N/1)=O)CSSCC/C=C/2)=O)=O)=O)=O

Sequence

vcXVXX

Molar mass

540.69 g/mol

Constitutional members:

5

Natural amino acids

1

D-Amino acids

2

N-terminus

cycle

C-terminus

cycle

Cyclic

yes

Members/cycle

multicyclic

Bond to form cycle

side chain-to-side chain (disulfide) + head-to-tail

Lipidation

no

Glycosylation

no

Route of administration

IV

Terminal half-life

3 hours

Protein binding

92-94%

Absorption and Bioavailability

-

References